

In the matter of the Canadian Anti-Doping Program;

**And in the matter of an anti-doping rule violation by Jonathan Stanley asserted by the
Canadian Centre for Ethics in Sport;**

File Outcome Summary

Summary

1. The Canadian Centre for Ethics in Sport (CCES) conducted an In-Competition Sample collection session on June 3, 2023, in Torbay, NL.
2. Mr. Jonathan Stanley (“the Athlete”) was selected for Doping Control. The Sample provided by the Athlete returned an Adverse Analytical Finding (AAF) for Trenbolone metabolite (epitrenbolone) (“Trenbolone”), Oxandrolone metabolites (“Oxandrolone”), Clostebol metabolites (“Clostebol”), Nandrolone and metabolites: 19-norandrosterone (“Nandrolone”), Drostanolone metabolites (“Drostanolone”), Testosterone and metabolites pregnanediol and 16-enol (“Testosterone”), and Methylphenidate and metabolite: ritalinic acid (“Methylphenidate”).
3. Following receipt of the CCES’s Notice of Charge asserting an anti-doping rule violation (ADRV) for the presence and Use of the Prohibited Substances, the Athlete signed an Early Admission and Acceptance of Sanction Form, thereby admitting the ADRV, waiving his right to a hearing and accepting all applicable Consequences.

Jurisdiction

4. The CCES is an independent not-for-profit organization incorporated under the federal laws of Canada that promotes ethical conduct in all aspects of sport in Canada. The CCES also maintains and implements the Canadian Anti-Doping Program (CADP), including providing anti-doping services to national Sport Organizations and their members.
5. As Canada’s National Anti-Doping Organization, the CCES is in compliance with the World Anti-Doping Code (“the Code”) and its mandatory International Standards. The CCES has implemented the Code and the International Standards through the CADP, the domestic rules which govern this proceeding. The purpose of the Code and of the CADP is to protect the rights of athletes to fair competition.
6. The Athlete is a member of and participates in the activities of the Canadian Powerlifting Union (CPU). According to CADP Rule 1.3, the CADP provisions apply to all members of, and Participants in activities of Sport Organizations adopting it. The CADP was issued for adoption by Canadian Sport Organizations on October 26, 2020. The CPU adopted the CADP on October 29, 2020. Therefore, as a Participant in CPU activities, the Athlete is subject to the CADP.

Doping Control

7. On June 3, 2023, the CCES conducted an In-Competition Sample collection session in Torbay, NL. Testing was conducted on CPU athletes as part of the CCES's domestic test distribution plan, all pursuant to the CADP.
8. The Athlete was notified that he had been selected for Doping Control and, together with the doping control officer from the CCES, completed the Sample collection process. The Athlete's Sample code number was 7088043.
9. On June 6, 2023, the Athlete's Sample was received for analysis by the INRS Centre Armand-Frappier Santé Biotechnologie ("the INRS"), a World Anti-Doping Agency (WADA) accredited laboratory in Laval, Quebec.

Results Management

10. The AAF was reported by the INRS on June 26, 2023. The Certificate of Analysis indicated the presence of Trenbolone, Oxandrolone, Clostebol, Nandroone, Drostanolone, Testosterone and Methylphenidate.
11. Trenbolone, Oxandrolone, Clostebol, Nandroone, Drostanolone, and Testosterone are classified as non-specified Prohibited Substances and Methylphenidate is classified as a Specified Substance on WADA's 2023 Prohibited List.
12. The CCES commenced an initial review into the Athlete's AAF and issued a notification of a potential ADRV on July 6, 2023.
13. On July 25, 2023, the CCES formally issued a Notice of Charge asserting an ADRV against the Athlete for the presence and Use of Prohibited Substances.
14. In accordance with CADP Rule 10.2.1.1, the sanction for an ADRV involving the presence and Use of Prohibited Substances is a four (4) year period of Ineligibility. The CCES asserted a four (4) year sanction within its Notice of Charge of June 26, 2023.

Confirmation of Violation and Sanction

15. In accordance with CADP Rule 10.8.1, the CCES informed the Athlete on July 25, 2023, that should the Athlete exercise their option to sign the Early Admission and Acceptance of Sanction Form, the Athlete would receive a one (1) year reduction of the four (4) year period of Ineligibility asserted by the CCES.
16. On August 12, 2023, the Athlete signed and submitted the Early Admission and Acceptance of Sanction Form to the CCES. Accordingly, effective August 12, 2023, an ADRV has been confirmed against the Athlete for the presence and Use of the identified Prohibited Substances. In accordance with CADP Rules 7.4.1, 10.2.1.1, 10.8.1 and 10.13.2.1, the sanction for this violation is a three (3) year period of Ineligibility which commenced on July 25, 2023, the date the Athlete was Provisionally Suspended, and concludes on July 24, 2026.

Further, in accordance with CADP Rule 10.10, any competitive results obtained by the Athlete, from date of Sample collection, shall be Disqualified.

17. The CCES now considers this case closed.

Dated at Ottawa, Ontario this 27th day of September 2023.



Kevin Bean
Executive Director, Sport Integrity
CCES